MyDosageBeta
Scan
ACTH(4-10) analogue

Semax

Russian synthetic heptapeptide derived from ACTH; nootropic and neuroprotective claims.

Human observational · t½ Short · 200–600 mcg, 1–3× daily

Start with a product

Pick what you have. We'll guide the rest.

Schedule, what to expect, side-effects to watch — built around your exact product.

Scan a productAdd manually
BHuman observationalHuman observationalACTH(4-10) analogue

Russian synthetic heptapeptide derived from ACTH; nootropic and neuroprotective claims.

Scientific Consensus Engine

Evidence Intelligence Score™

Heuristic — no indexed evidence yet
5.1/ 10
Overall confidence
Emerging
Outlook
Emerging
Evidence maturity
  1. Preclinical
  2. Pilot human← current
  3. RCT
  4. Multi-RCT
  5. Meta-analysis

Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.

Eight-dimension breakdown
  1. Human evidence
    Weight of RCT and observational data
    6.3
  2. Safety maturity
    Follow-up depth and adverse-event signal
    5.3
  3. Mechanism confidence
    Pathway specificity and clarity
    6.4
  4. Clinical readiness
    Distance to physician-prescribable use
    5.4
  5. Research momentum
    Recency of indexed clinical evidence
    5.0
  6. Study consistency
    Effect direction across cohorts
    3.0
  7. Long-term data
    Follow-up beyond initial trial windows
    3.6
  8. Translational confidence
    Animal → human signal preservation
    6.1
Strongest supported claim

Early human signals exist, primarily from observational and pilot work — directional, not definitive.

Weakest / unclear

Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.

Major unknowns

Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.

Scientific outlook

Outlook: directional. The next 12–24 months of registered trials will determine whether the early signal holds.

Mechanism
Modulates BDNF, dopamine, and serotonin systems; neuroprotective in stroke models.
Clinical evidence · 3 studies indexed

Cognition & focus

2 studies

Mood regulation

1 study
Observed research protocols · 2 regimens

Cognition & focus

1 regimen
Clinical trialsource ↗

Generally well tolerated; mild local nasal irritation reported. Not approved outside Russia/CIS.

Outpatient cognitive courses typically 10–14 days; stroke protocols 5–10 days.

Mood regulation

1 regimen
Preclinicalsource ↗

Mild nasal irritation; long-term safety not established.

Limited human mood-specific RCT data; mechanism supported by preclinical neurochemistry.

These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.

Citations
What we don't know yet
  • —Long-term safety beyond reported study durations.
  • —Effect size in populations under-represented in the cited trials.
  • —Interactions with concomitant medications outside listed contraindications.

We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.

Editorial team
Independent · No affiliate revenue
Reviewed quarterly
Brands carrying this peptide

1 brand across three tiers.

Research-use only

1 brand

Sold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.